EVERSANA is broadening the reach of its AI-powered commercialization platform beyond marketing agency operations, adding capabilities for medical affairs, market research, commercial operations and field sales engagement. The expansion reflects a wider shift in the pharmaceutical industry from isolated generative AI experiments toward connected enterprise workflows designed to improve efficiency while maintaining regulatory oversight, scientific rigor and human review.

Artificial intelligence is moving deeper into pharmaceutical commercialization, but the industry's challenge is no longer simply proving that AI can automate individual tasks. The harder problem is connecting those capabilities across the highly regulated workflows that move a therapy from development toward patients.

EVERSANA is addressing that challenge by expanding its AI-powered commercialization platform into medical affairs, market research, field sales engagement and other commercial functions.

The company said its platform, originally developed to transform marketing agency operations, now includes capabilities for medical information and market research, as well as medical, legal and regulatory review (MLR) automation and analytics. Additional capabilities are being developed for market access, patient services and sales enablement.

The expansion puts EVERSANA among a growing group of technology providers attempting to move pharmaceutical companies from disconnected AI tools toward broader, governed AI operating models.

For life sciences organizations, that distinction is important. Marketing, medical affairs, market access and sales teams often work with overlapping information but operate within different processes, systems and regulatory requirements. AI can potentially reduce that fragmentation, but only when enterprise data, workflows and governance are connected.

From AI Agency to Enterprise Commercialization Platform

EVERSANA's platform uses agentic AI orchestration, workflow automation and enterprise data capabilities to support content development, knowledge management and commercial workflows.

The company describes the system as an evolution of its AI Agency, which was initially focused on marketing operations.

Agentic AI differs from conventional generative AI applications because it can coordinate multiple steps in a workflow rather than simply generate a response to an individual prompt. In a commercialization environment, that could mean orchestrating activities such as retrieving approved knowledge, creating content, routing materials for review, analyzing performance and maintaining reusable assets.

The potential enterprise benefit is not just faster content creation. It is the ability to reuse trusted knowledge across teams while reducing repetitive operational work.

That matters particularly in pharmaceuticals, where content must often pass through rigorous medical, legal and regulatory review before reaching healthcare professionals or consumers.

EVERSANA's new MLR automation and analytics capabilities are therefore strategically significant. Automating parts of review workflows could reduce bottlenecks, although human oversight remains essential when content involves medical claims, safety information or regulatory considerations.

AI Moves Into Medical Affairs and Market Research

The expansion into medical affairs and market research represents another step toward a more connected commercialization model.

Medical affairs teams manage scientific information and relationships with healthcare professionals, while market research teams generate insights about customers, competitors and market dynamics. Historically, those functions have often relied on specialized processes and data environments.

AI can create opportunities to search institutional knowledge faster, summarize large datasets, identify patterns and support decision-making.

The challenge is ensuring that the information feeding those systems is accurate, current and properly governed.

This is where EVERSANA's emphasis on enterprise data and knowledge management becomes important. A pharmaceutical AI system cannot be treated like a general-purpose consumer chatbot. The value depends heavily on controlled information sources, permissions, auditability and clear boundaries around what the system can generate or recommend.

That requirement is becoming a defining characteristic of enterprise AI in regulated industries.

The Shift From AI Pilots to AI Operating Models

EVERSANA CEO Mark Thierer described the pharmaceutical sector as reaching an "inflection point," with organizations moving beyond isolated AI pilots and looking for ways to scale AI across commercialization.

The observation reflects a broader enterprise technology trend.

Companies have spent the past several years experimenting with generative AI for tasks such as content creation, research and customer service. The next phase is increasingly focused on integrating AI into repeatable workflows and measuring its operational impact.

For pharmaceutical companies, this could mean connecting AI across the commercialization lifecycle rather than deploying separate tools for marketing, medical information, sales enablement and market research.

That model also creates a stronger case for centralized governance.

Instead of allowing every department to adopt independent AI applications, enterprises can establish common data policies, security controls, model governance and approval processes while allowing teams to use specialized workflows.

Competition Is Moving Toward AI Infrastructure

EVERSANA's expansion places it in a competitive landscape that includes enterprise software providers, cloud platforms, specialized life sciences technology companies and AI vendors.

Large technology ecosystems such as Microsoft, Google, Amazon and Salesforce are investing heavily in enterprise AI, data platforms and workflow automation. Their scale gives pharmaceutical companies access to broad infrastructure, while specialized providers can differentiate through industry-specific workflows and regulatory expertise.

EVERSANA's positioning is closer to the latter category. Its advantage is not simply access to AI models but the ability to combine AI orchestration with commercialization knowledge and life sciences processes.

That distinction could become increasingly important as pharmaceutical companies evaluate AI investments.

A general-purpose AI platform can provide powerful underlying capabilities, but regulated organizations often need domain-specific workflows, approved content libraries, specialized review processes and compliance controls.

The emerging competitive question is therefore shifting from "Who has the best AI model?" to "Who can safely integrate AI into the highest-value enterprise workflows?"

Market Landscape

The life sciences industry is entering a more mature phase of enterprise AI adoption. Gartner has forecast that by 2026, more than 80% of enterprises will have used generative AI APIs or deployed generative AI-enabled applications, up from less than 5% in 2023.

For pharmaceutical organizations, adoption is likely to be constrained less by access to AI technology than by data quality, governance, regulatory requirements and workflow integration.

That creates an opportunity for specialized commercialization platforms. Vendors that can connect AI with validated enterprise knowledge and existing business processes may have an advantage over standalone productivity tools.

Strategic Outlook

EVERSANA's platform expansion points toward a future in which pharmaceutical commercialization becomes increasingly orchestrated through shared AI and data infrastructure.

The company's planned expansion into market access, patient services and sales enablement could extend that model across even more functions.

The strategic test will be whether these capabilities can generate measurable improvements in speed and efficiency without weakening the scientific, medical and regulatory controls required by the industry.

If successful, AI commercialization platforms could become a foundational layer connecting marketing, medical affairs, research, sales and patient-facing operations.

Top Insights

• EVERSANA is expanding its AI commercialization platform beyond marketing into medical affairs, research and operations, increasing AI's role across pharmaceutical workflows.
• Agentic AI orchestration could help life sciences teams automate multi-step commercialization processes while preserving human oversight and regulatory governance.
• MLR automation and analytics target a major operational bottleneck, potentially accelerating pharmaceutical content workflows without removing medical and regulatory review.
• Enterprise knowledge management is becoming central to pharmaceutical AI as organizations seek reusable, governed information rather than disconnected generative AI tools.
• EVERSANA's strategy reflects a broader market shift from AI experimentation toward integrated commercialization operating models connecting data, workflows and specialized teams.

Get in touch with our MarTech Experts